Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection—comparison with omeprazole and lansoprazole

Abstract

INTRODUCTIONSince the signi®cant impact of Helicobacter pylori infection in the development of most gastric diseases has been established, curative therapy for the infection has been of growing clinical interest. A recent trend in curative therapy is the so-called triple therapy, 1 which consists of a proton pump inhibitor (PPI) and two different antimicrobials. Various regimens of triple therapy have been reported that utilize different combinations of proton pump inhibitor or antimicrobials, with respect to dosage and duration of treatment. 2,3 Among these, higher dosages of proton pump inhibitor have been considered to be more effective 4 and there are many reports regarding the ef®cacy of proton pump inhibitor/AC regimens using omeprazole, lansoprazole and pantoprazole. 2, 5±7 Rabeprazole, a recently developed proton pump inhibitor, has become available, and has been considered to

Safety and efficacy of 7‐day rabeprazole‐ and omeprazole‐based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease

“…[12][13][14][15] In terms of H. pylori eradication, the effectiveness of rabeprazole-based triple therapy has been shown in patients with chronic gastritis, peptic ulcer disease and non-ulcer dyspepsia. [16][17][18][19][20] The present study was designed to determine whether rabeprazole, in combination with clarithromycin and either amoxicillin or metronidazole, is therapeutically equivalent to the same omeprazole-based regimens in the eradication of H. pylori in subjects with documented peptic ulcer disease and H. pylori infection.…”

Comparison of efficacies of dual therapy and triple therapy using rabeprazole in second‐line eradication of Helicobacter pylori in Japan

“…RPZ-based eradication therapies 7,[25][26][27] as the first-line therapy. Similar eradication rates have been reported for triple therapies using RPZ as for those with omeprazole (OPZ) and lansoprazole (LPZ) .…”

“…[1][2][3] Triple therapy comprising a proton pump inhibitor (PPI) and two antibiotics yields high eradication rates ranging from 80% to 95% but not 100%. [4][5][6][7] With the increased use of H. pylori eradication treatments, the overall number of cases of failed eradication has increased. It has been reported that ranitidinebismuth-based triple therapies 8,9 and quadruple therapies [PPI + bismuth + metronidazole (MNZ) + tetracycline] [10][11][12] are the most effective second-line therapies in Western countries.…”

Resistance to Antimicrobialagents in Eradication of Helicobacter Pylori Infection

“…In Japan, the rate of eradication by triple therapy ranges from 80% to 95% (Miwa, Ohkura et al, 1999). Many studies have reported that there are no significant differences in the rate of eradication when any of the 3 agents, omeprazole (OPZ), lansoprazole (LPZ), and rabeprazole (RPZ), ANNALS OF Cancer Research and Therapy is used as a PPI (Miwa, Ohkura et al, 1999;Inaba, Mizuno et al,2002) however, reported that RPZ achieved a higher rate of eradication than LPZ. In addition, several studies have indicated that there are no significant differences in the rate of eradication among different doses of RPZ as a PPI, 10mg, 20mg, and 40mg (Hokari, Sugiyama et al, 2001;Miwa, Yamada et al, 2000).…”

“…The eradication regimen consists of triple therapy with a proton pump inhibitor (PPI), amoxicillin (AMPC), and clarithromycin (CAM) [PPI/AC]. In Japan, the rate of eradication by triple therapy ranges from 80% to 95% (Miwa, Ohkura et al, 1999). Many studies have reported that there are no significant differences in the rate of eradication when any of the 3 agents, omeprazole (OPZ), lansoprazole (LPZ), and rabeprazole (RPZ), ANNALS OF Cancer Research and Therapy is used as a PPI (Miwa, Ohkura et al, 1999;Inaba, Mizuno et al,2002) however, reported that RPZ achieved a higher rate of eradication than LPZ.…”